দেশে গবেষণার পরিবেশ dailynayadiganta.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailynayadiganta.com Daily Mail and Mail on Sunday newspapers.
Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111 2B Global Metastatic Cancer Market - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market
MELBOURNE, Australia (BUSINESS WIRE)
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The Company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth US$111.2 Billion by 2027, according to current analysis by Emergen Research.